10x Genomics is emerging as a critical entity in the rapidly expanding field of AI-powered biological data. The company has shown significant progress in its operational efficiency and financial returns, marked by consistent growth in single-cell analysis and overall revenue. This upward trajectory is largely attributed to its innovative technology, which is instrumental in generating the detailed biological insights essential for training advanced artificial intelligence models. Industry analysts are taking note, underscoring the company's strategic importance in the intersection of biotechnology and AI.
William Blair Upgrades 10x Genomics Amidst Surging AI Demand
On Monday, March 31, 2026, analyst Matt Larew of William Blair issued an upgrade for 10x Genomics Inc. (NASDAQ: TXG), recognizing its leadership in biological technology. This positive re-evaluation stems from the company's strong position to capitalize on a revitalized market for biological data and the escalating demand for extensive datasets to train AI systems. Larew's assessment emphasized the company's critical function in facilitating high-resolution biological understanding, which is indispensable for constructing sophisticated decision-making models.
The company's performance metrics have also contributed to the upgrade. 10x Genomics reported a fourth-quarter loss of 13 cents per share, outperforming the Wall Street estimate of 20 cents per share. Sales for the quarter reached an impressive $166.03 million, surpassing the consensus forecast of $159.27 million. Looking ahead, the company projects fiscal year 2026 sales to be between $600 million and $625 million, compared to the market consensus of $611.58 million. These figures reflect a stabilizing single-cell performance, with double-digit volume growth for the fourth consecutive quarter, alongside a modest but significant increase in revenue.
While AI-related initiatives constituted a relatively small portion of the company's revenue in 2025, William Blair anticipates this sector will evolve into a major growth driver. The escalating need for proprietary, high-quality, large-scale biological datasets is expected to fuel this expansion. Further bolstering this outlook, Bioptimus recently unveiled its Spatial Tissue Embedding Learning Atlas (STELA), a large-scale multinational spatial data generation project. This initiative, anchored by a partnership with 10x Genomics, leverages the Xenium spatial transcriptomics platform to profile up to 100,000 patient tissue specimens. Analyst Larew views this collaboration as a significant endorsement of Xenium’s role as the premier platform for AI-scale spatial data generation. Following these developments, 10x Genomics shares experienced a notable increase, rising 4.49% to $20.70 by Tuesday's publication time.
The increasing integration of AI in scientific research, particularly in biotechnology and healthcare, signals a paradigm shift. Companies like 10x Genomics, with their advanced technologies for generating high-resolution biological data, are not just participants but pioneers in this evolution. Their contributions are vital for pushing the boundaries of AI applications in understanding complex biological systems, paving the way for groundbreaking discoveries and personalized medical solutions. This highlights the immense potential for growth in companies that bridge cutting-edge technology with critical scientific needs.